Form 4: Cingulate CEO Acquires Shares & Warrants in Private Placement

Cingulate Inc.'s CEO and Director, Shane J. Schaffer, acquired common stock and warrants through a private placement, increasing his indirect beneficial ownership.

Summary

• Shane J. Schaffer, CEO and Director of Cingulate Inc., acquired 6,809 shares of common stock and 5,447 warrants indirectly through Fountainhead Shrugged, LLC.
• The common stock was acquired at a price of $5.04 per share, and the warrants at $0.1 per warrant, with an exercise price of $5.04.
• This acquisition was part of a private placement previously disclosed in a Form 8-K on January 28, 2026.
• Following the transaction, Schaffer indirectly beneficially owns 10,175 shares of common stock and 5,447 warrants via Fountainhead Shrugged, LLC.
• Schaffer also directly owns 173 shares of common stock.
• The warrants become exercisable upon Cingulate Inc. obtaining stockholder approval for the private placement, as required by Nasdaq rules, and expire 36 months after the exercise date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as insider buying by a CEO typically indicates confidence. However, the contingency on stockholder approval for warrant exercisability introduces a minor element of uncertainty.

Positives

• CEO and Director Shane J. Schaffer increased his stake in the company, indicating confidence in Cingulate Inc.'s future prospects.
• The acquisition was part of a private placement, suggesting capital infusion for the company.

Negatives

• Warrant exercisability is contingent on stockholder approval, introducing a potential delay or uncertainty.

Risks

• The warrants are not immediately exercisable and require stockholder approval of the private placement, which could be denied or delayed.
• The company is subject to Nasdaq rules regarding stockholder approval for private placements, which could impact the timing and certainty of warrant exercise.

Future Outlook

The exercisability of the acquired warrants is contingent upon Cingulate Inc. obtaining stockholder approval for the private placement, as mandated by Nasdaq rules. The warrants will expire 36 months after their exercise date.

Industry Context

StockSavvy.ai notes that insider purchases, especially by a CEO and Director, often signal management's confidence in the company's future prospects. This private placement suggests Cingulate Inc. is raising capital, a common activity for growth-oriented or development-stage companies, particularly in the biotech or pharmaceutical sectors where Cingulate operates.

Stakeholder Impact

• Shareholders: Potential positive signal due to insider buying, but also potential dilution from the private placement and future warrant exercise.
• Company: Receives capital from the private placement.

Next Steps

• Cingulate Inc. needs to obtain stockholder approval for the private placement to make the warrants exercisable.

Key Dates

Recommendation

The insider purchase by the CEO is a positive indicator of management confidence, suggesting potential upside. However, the transaction is part of a private placement, which can lead to dilution, and the warrant exercisability is contingent on stockholder approval, introducing a degree of uncertainty. Without further financial details or strategic updates, a 'hold' recommendation is prudent, awaiting more comprehensive information on the company's performance and the outcome of the stockholder vote.

Keywords

Cingulate Inc., CING, Shane J. Schaffer, Form 4, Insider Trading, Stock Acquisition, Warrants, Private Placement, CEO, Director, Beneficial Ownership